NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
About The Author
Air Quality During the COVID-19: PM 2.5 Analysis in the 50 Most Polluted Capital Cities in the World
Decreasing High Risk Exposures for Healthcare-workers through Universal Masking and Universal SARS-CoV-2 Testing upon entry to a Tertiary Care Facility
CDC CDC Newsroom Coronavirus COVID19 Disease flu Health health threats healthy choice Infection influenza Letter Media MEDLINE National Center for Biotechnology Information National Institutes of Health National Library of Medicine NCBI Newsroom NIH NLM Online Outbreak Pandemic Patients Potential Press prevention protecting people PubMed Abstract Release Report Review SARSCoV2 saving lives saving money science secure nation Study Telebriefing Treatment Update Updates US federal agency virus